ReviewJournal of cellular and molecular medicine2012
Perivascular cells for regenerative medicine.
Review in Journal of cellular and molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 299 citations in OpenAlex.
- Coupling intraoperative bioprinting and surgical micropuncture for synergistic scaffold vascularization.Biomaterials · 2026Article
- Revisiting MSC heterogeneity: significance of the CD73Frontiers in bioengineering and biotechnology · 2026Article
- Hurdles to overcome for mesenchymal stem cell translation from bench to bedside.World journal of stem cells · 2025Review
- Mesenchymal-to-epithelial transition of perivascular cells contributes to endometrial re-epithelialization.Nature communications · 2025Article
- Across Barriers: Blood-Brain and Gut Barrier Signaling in Psychiatric Disorders.Journal of neurochemistry · 2025Review
- Participation of the Periosteum, Endosteum, and Hematogenous Marrow in the Early Osseointegration of a Titanium Implant Inserted in Contact with the Hematogenous Marrow.Medicina (Kaunas, Lithuania) · 2025Article
- Functional heterogeneity of meniscal fibrochondrocytes and microtissue models is dependent on modality of fibrochondrocyte isolation.Cell proliferation · 2025Article
- Article
- Serum metabonomics reveal the effectiveness of human placental mesenchymal stem cell therapy for primary sclerosing cholangitis.Stem cell research & therapy · 2024Article
- Review
- The innate immune regulator MyD88 dampens fibrosis during zebrafish heart regeneration.Nature cardiovascular research · 2024Article
- Isolation of Perivascular Mesenchymal Progenitor Cells from Human Adipose Tissue by Flow Cytometry.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Scalable Generation of Pre-Vascularized and Functional Human Beige Adipose Organoids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- The therapeutic value of adipose-derived pericyte transplantation after intracerebral hemorrhage in rats.Journal of molecular histology · 2023Article
- Extracellular Matrix Remodeling in Vascular Disease: Defining Its Regulators and Pathological Influence.Arteriosclerosis, thrombosis, and vascular biology · 2023Review
- hapln1aNature communications · 2023Article
- Definitive Endodermal Cells Supply an in vitro Source of Mesenchymal Stem/Stromal Cells.Communications biology · 2023Article
- The participation of tumor residing pericytes in oral squamous cell carcinoma.Scientific reports · 2023Article
- CXCR4 mediates the effects of IGF-1R signaling in rodent bone homeostasis and fracture repair.Bone · 2023Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Mesenchymal stem/stromal cells (MSC) are currently the best candidate therapeutic cells for regenerative medicine related to osteoarticular, muscular, vascular and inflammatory diseases, although these cells remain heterogeneous and necessitate a better biological characterization. We and others recently described that MSC originate from two types of perivascular cells, namely pericytes and adventitial cells and contain the in situ counterpart of MSC in developing and adult human organs, which can be prospectively purified using well defined cell surface markers. Pericytes encircle endothelial cells of capillaries and microvessels and express the adhesion molecule CD146 and the PDGFRβ, but lack endothelial and haematopoietic markers such as CD34, CD31, vWF (von Willebrand factor), the ligand for Ulex europaeus 1 (UEA1) and CD45 respectively. The proteoglycan NG2 is a pericyte marker exclusively associated with the arterial system. Besides its expression in smooth muscle cells, smooth muscle actin (αSMA) is also detected in subsets of pericytes. Adventitial cells surround the largest vessels and, opposite to pericytes, are not closely associated to endothelial cells. Adventitial cells express CD34 and lack αSMA and all endothelial and haematopoietic cell markers, as for pericytes. Altogether, pericytes and adventitial perivascular cells express in situ and in culture markers of MSC and display capacities to differentiate towards osteogenic, adipogenic and chondrogenic cell lineages. Importantly, adventitial cells can differentiate into pericyte-like cells under inductive conditions in vitro. Altogether, using purified perivascular cells instead of MSC may bring higher benefits to regenerative medicine, including the possibility, for the first time, to use these cells uncultured.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.